Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127270) titled 'Trastuzumab Rezetecan or Irinotecan Liposome (II) Combined with Anlotinib in the Treatment of Patients with Relapsed or Metastatic Small Round Cell Sarcoma and Other HER2-Abnormal Solid Tumors: A Prospective, Multi-Cohort, Phase Ib/II Clinical Study' on June 28.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Recurrent or metastatic small round cell sarcoma and other HER2-aberrant solid tumors.
Intervention:
Group A1:irinotecan liposome (II) in combination with anlotinib
Group A2:irinotecan liposome (II) in combination with anlotinib...